Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect

Página do item simplificado
dc.contributor.authorDalmora, M. E.
dc.contributor.authorDalmora, S. L.
dc.contributor.authorOliveira, Anselmo Gomes de [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal de Sergipe (UFS)
dc.date.accessioned2014-05-20T13:24:23Z
dc.date.available2014-05-20T13:24:23Z
dc.date.issued2001-07-03
dc.description.abstractTopical formulations of piroxicam were evaluated by determination of their in vitro release and in vivo anti-inflammatory effect. The in vitro release assay demonstrated that the microemulsion (ME) systems provided a reservoir effect for piroxicam release. However, the incorporation of the ME into carboxyvinilic gel provoked a greater reduction in the release of piroxicam than the ME system alone. Anti-inflammatory activity was carried out by the cotton pellet granuloma inhibition bioassay. Topical anti-inflammatory effect of the piroxicam inclusion complex/ME contained in carboxyvinilic gel showed significant inhibition of the inflammation process (36.9%, P < 0.05). Subcutaneous administration of the drug formulations showed a significant effect on the inhibition of inflammation, 68.8 and 70.5%, P <0.05, when the piroxicam was incorporated in ME and in the combined system beta -cyclodextrin (B-CD)/ME, respectively, relative to the buffered piroxicam (42.2%). These results demonstrated that the ME induced prolonged effects, providing inhibition of the inflammation for 9 days after a single dose administration. (C) 2001 Elsevier B.V. B.V. All rights reserved.en
dc.description.affiliationUNESP, Fac Ciências Farmaceut, Dept Farmacos & Medicamentos, BR-14801902 Araraquara, SP, Brazil
dc.description.affiliationUniversidade Federal de Santa Maria (UFSM), Ctr Ciências Saude, Dept Farm Ind, BR-97119900 Santa Maria, RS, Brazil
dc.description.affiliationUnespUNESP, Fac Ciências Farmaceut, Dept Farmacos & Medicamentos, BR-14801902 Araraquara, SP, Brazil
dc.format.extent45-55
dc.identifierhttp://dx.doi.org/10.1016/S0378-5173(01)00692-5
dc.identifier.citationInternational Journal of Pharmaceutics. Amsterdam: Elsevier B.V., v. 222, n. 1, p. 45-55, 2001.
dc.identifier.doi10.1016/S0378-5173(01)00692-5
dc.identifier.issn0378-5173
dc.identifier.lattes9114495952533044
dc.identifier.urihttp://hdl.handle.net/11449/7543
dc.identifier.wosWOS:000169704300005
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Pharmaceutics
dc.relation.ispartofjcr3.862
dc.relation.ispartofsjr1,172
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectpiroxicampt
dc.subjectbeta-cyclodextrinpt
dc.subjectmicroemulsionpt
dc.subjectanti-inflammatory effectpt
dc.subjectin vitro drug releasept
dc.titleInclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effecten
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
unesp.author.lattes9114495952533044[3]
unesp.author.orcid0000-0002-0107-9940[3]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Fármacos e Medicamentos - FCFAR